# A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

> **NCT05801783** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shanghai Yunying Medical Technology** · enrollment: 10 (estimated)

## Conditions studied

- Ovarian Cancer
- Peritoneal Carcinomatosis
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Recombinant oncolytic herpes simplex virus type 1 (R130)

## Key facts

- **NCT ID:** NCT05801783
- **Lead sponsor:** Shanghai Yunying Medical Technology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-02
- **Primary completion:** 2024-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05801783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05801783, "A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05801783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*